The RIVAWAR Trial and ACS Guidelines for LV Thrombus

Author(s):

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP ,Aislinn Antrim, Managing Editor

Host Craig Beavers spoke with Arthur Allen, PharmD, for the latest updates from the RIVAWAR trial and the newest ACS guidelines.

Host Craig Beavers spoke with Arthur Allen, PharmD, for the latest updates from the RIVAWAR trial of rivaroxaban and a discussion of the newest Acute Coronary Syndrome Guidelines for left ventricular thrombus.

For more information:

Management of Patients at Risk for and With Left Ventricular Thrombus: A Scientific Statement From the American Heart Association
Anticoagulation Forum Rapid Resources LV Thrombus
2025 ACC/AHA Guidelines
ACC 2025: Rivaroxaban Comparable to Warfarin in Left Ventricular Blood Clots